Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 34kWORD 19k
10 July 2020
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-002697/2020

The Commission is aware that some countries are considering the use of so-called ‘immunity passports’ or ‘health passports’ as part of the lifting of confinement measures. However, the European Centre for Disease Prevention and Control (ECDC) advises that there is currently limited evidence on lasting immunity(1).

In its Risk Assessment of 11 June 2020, the ECDC states that most persons infected with coronavirus develop antibodies after infection. However, the longevity of the antibody response is still unclear. The quantity, quality and duration of the human immune response to COVID-19 is presently unclear.

As a consequence, there is not enough scientific basis for using serology or other immune markers to determine access to public facilities, or take decisions on travel or employment. The World Health Organisation has also cautioned against using immunity certificates(2).

The Commission will continue to explore this issue, always placing scientific evidence as the basis for public health policy. The Commission is also helping Member States to coordinate national responses to the pandemic through the Health Security Committee.

Last updated: 13 July 2020Legal notice - Privacy policy